Safety of Dupilumab and Risk of Cutaneous T-Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data-Driven Guide to Counseling Patients and Families
Listen to this summary
The authors investigate the safety of dupilumab in pediatric patients with atopic dermatitis, specifically addressing concerns about the potential increased risk of cutaneous T-cell lymphoma (CTCL) associated with the treatment. They aim to provide evidence-based recommendations for monitoring and counseling families, particularly in light of recent data and the challenges posed by the diagnostic overlap between atopic dermatitis and CTCL.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.

More from Pediatric dermatology
View all →Jun 1, 2026 · Pediatric dermatology
Unilateral Forearm Ulceration in a Newborn: Thinking Outside the Box (Compartment)
May 31, 2026 · Pediatric dermatology
Ten-Year Epidemiology and Antimicrobial Susceptibility of Pediatric Staphylococcal Scalded Skin Syndrome: A Retrospective Study From a Tertiary Referral Center
More in Dermatology
View all →Nov 19, 2026 · Lancet (London, England)
Spontaneous coronary artery dissection: implications for women's health, clinical care, and future research.
Nov 19, 2026 · Lancet (London, England)
Reproductive health in women in Britain from 2010 to 2024: findings from repeated, cross-sectional National Surveys of Sexual Attitudes and Lifestyles (Natsal).
Nov 19, 2026 · Lancet (London, England)
Seasonal mass vaccination with R21/Matrix-M against malaria in The Gambia and Burkina Faso: an open-label, cluster-randomised, controlled trial.
Nov 19, 2026 · The New England journal of medicine
Assessing Multiple Treatment Regimens for Tuberculosis.
Nov 18, 2026 · The New England journal of medicine
Acute Respiratory Distress Syndrome.
Nov 17, 2026 · Lancet (London, England)
Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial.
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR


